79 related articles for article (PubMed ID: 2545422)
1. Reversion of tumorigenicity in an EBV-converted Burkitt's lymphoma line.
Klein G
Ciba Found Symp; 1989; 142():36-48; discussion 48-53. PubMed ID: 2545422
[TBL] [Abstract][Full Text] [Related]
2. Forward and reverse changes in Ig/myc translocation carrying tumors.
Klein G
Princess Takamatsu Symp; 1989; 20():135-42. PubMed ID: 2562178
[TBL] [Abstract][Full Text] [Related]
3. Immunological aspects of B-cell derived tumors in humans and rodents.
Klein G
Princess Takamatsu Symp; 1988; 19():3-13. PubMed ID: 2855874
[TBL] [Abstract][Full Text] [Related]
4. Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.
Jox A; Taquia E; Vockerodt M; Draube A; Pawlita M; Möller P; Bullerdiek J; Diehl V; Wolf J
Cancer Res; 1998 Nov; 58(21):4930-9. PubMed ID: 9810002
[TBL] [Abstract][Full Text] [Related]
5. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
6. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
7. EBV-B cell interactions: immortalization, rescue from apoptosis, tumorigenicity (a short review).
Klein G
Acta Microbiol Immunol Hung; 1996; 43(2-3):97-105. PubMed ID: 8876725
[TBL] [Abstract][Full Text] [Related]
8. Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines.
Pokrovskaja K; Ehlin-Henriksson B; Bartkova J; Bartek J; Scuderi R; Szekely L; Wiman KG; Klein G
Cell Growth Differ; 1996 Dec; 7(12):1723-32. PubMed ID: 8959341
[TBL] [Abstract][Full Text] [Related]
9. Selective loss of integrated Epstein-Barr virus genomes after long-term cultivation of Burkitt's lymphoma x B-lymphoblastoid cell hybrids due to chromatin instability at the integration site.
Wolf J; Jox A; Skarbek H; Pukrop T; Bartnitzke S; Pawlita M; Diehl V; Bullerdiek J
Virology; 1995 Sep; 212(1):179-85. PubMed ID: 7676627
[TBL] [Abstract][Full Text] [Related]
10. The cytogenetics of human B lymphoid malignancy: studies in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell lines.
Steel CM; Morten JE; Foster E
IARC Sci Publ; 1985; (60):265-92. PubMed ID: 2998993
[TBL] [Abstract][Full Text] [Related]
11. Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line.
Torsteinsdóttir S; Andersson ML; Avila-Cariño J; Ehlin-Henriksson B; Masucci MG; Klein G; Klein E
Int J Cancer; 1989 Feb; 43(2):273-8. PubMed ID: 2645221
[TBL] [Abstract][Full Text] [Related]
12. A potential role for antigen selection in the clonal evolution of Burkitt's lymphoma.
Jain R; Roncella S; Hashimoto S; Carbone A; Francia di Celle P; Foa R; Ferrarini M; Chiorazzi N
J Immunol; 1994 Jul; 153(1):45-52. PubMed ID: 8207254
[TBL] [Abstract][Full Text] [Related]
13. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
14. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
16. Etiology of endemic Burkitt's lymphoma.
Olweny CL
IARC Sci Publ; 1984; (63):647-53. PubMed ID: 6100285
[TBL] [Abstract][Full Text] [Related]
17. Conditioned tumorigenicity of activated oncogenes.
Klein G; Klein E
Cancer Res; 1986 Jul; 46(7):3211-24. PubMed ID: 3011242
[TBL] [Abstract][Full Text] [Related]
18. Reduced signal transduction through glucocorticoid receptor in Burkitt's lymphoma cell lines.
Sinclair AJ; Jacquemin MG; Brooks L; Shanahan F; Brimmell M; Rowe M; Farrell PJ
Virology; 1994 Mar; 199(2):339-53. PubMed ID: 8122366
[TBL] [Abstract][Full Text] [Related]
19. Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma.
Rooney CM; Rickinson AB; Moss DJ; Lenoir GM; Epstein MA
IARC Sci Publ; 1985; (60):249-64. PubMed ID: 2998992
[TBL] [Abstract][Full Text] [Related]
20. Cell phenotype-dependent splicing reflecting differential promoter usage for EBNA transcripts in EBV-carrying cells.
Hu LF; Chen F; Altiok E; Winberg G; Klein G; Ernberg I
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():248-60. PubMed ID: 10895161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
